Under the Radar: Liquidia Stock Soars After Settling Patent Fight -- WSJ

By Xavier Martinez

Shares of Liquidia surged nearly 30% this morning after the company settled six lawsuits with rival United Therapeutics, ending multiyear litigation that had threatened to restrict sales of Liquidia's main drug, called Yutrepia.

Morrisville, N.C.-based Liquidia said it will pay around $380 million to United Therapeutics through 2027. Yutrepia, an inhaled lung drug, will stay on the market for pulmonary arterial hypertension, a disease that narrows the arteries in the lungs.

In September, a judge found Liquidia infringed a United Therapeutics patent covering the use of the active ingredient in Yutrepia to treat patients with a different lung disease. Liquidia shares fell 57% that day. As part of its settlement, Liquidia agreed not to appeal and said it will stop promoting Yutrepia for that condition.

This item is part of a Wall Street Journal live coverage event. The full stream can be found by searching P/WSJL (WSJ Live Coverage).

(END) Dow Jones Newswires

October 14, 2026 10:24 ET (14:24 GMT)